If You Invested in Quantum-Si Incorporated (QSI)

Quantum-Si Incorporated (QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis. Traded on the Nasdaq Stock Market under the symbol QSI, the company develops and commercializes research tools that enable protein detection and analysis, including a hardware, consumable, and software solution built around a proprietary universal single-molecule detection platform for Next-Generation Protein Sequencing (NGPS). According to company disclosures, Quantum-Si describes itself as transforming proteomics with a benchtop platform that brings single-molecule protein analysis to laboratories and enables real-time, kinetic-based detection of proteins.

Quantum-Si’s platform is designed to allow researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights. The company states that its technology provides high-resolution information on proteins by sequencing them at the single-molecule level, supporting applications where detailed characterization of protein sequences and behavior is important. By making protein analysis simpler, faster, and more informative, Quantum-Si positions its tools to help accelerate proteomic discoveries.

Business focus and core technology

Based on its public descriptions and filings, Quantum-Si operates in the Other Measuring and Controlling Device Manufacturing industry within the broader manufacturing sector, with a clear specialization in proteomics research tools. The company has developed a proprietary universal single-molecule detection platform that enables NGPS, which it describes as the ability to sequence proteins. This platform underpins a benchtop instrument, associated consumable kits, and software for data analysis.

The company emphasizes single-molecule protein analysis and real-time kinetic-based detection as core capabilities. Its platform is intended to give researchers direct access to functional protein information, rather than relying solely on indirect or bulk measurements. Quantum-Si highlights that this approach can help users move away from complex, multistep workflows toward more streamlined protein analysis.

Products, chemistry kits, and data analysis tools

Quantum-Si’s commercial and development activities, as reflected in recent announcements, center on sequencing chemistry kits, library preparation kits, and data analysis tools that run on its benchtop platform. The company has launched a V4 Sequencing Kit, which it reports is compatible with its Platinum and Platinum Pro instruments. According to Quantum-Si, the V4 Sequencing Kit improves sequencing coverage through:

• Recognition of additional amino acids, including glycine, with enhanced recognition of alanine and serine.
• An enzyme designed to cut through the amino acid directly preceding proline, enabling analysis of proline-rich domains.
• New algorithms to improve precision and handling of protein mixtures.

The company states that these changes increase the number of sequenceable peptides compared to its prior V3 Sequencing Kit and support applications such as antibody sequencing and analysis of complex protein mixtures. Quantum-Si also notes that the V4 Sequencing Kit supports barcoding of up to 24-plex samples, which it associates with improved analysis of protein mixtures common in certain workflows.

In addition to sequencing chemistry, Quantum-Si has announced a Version 3 Library Preparation Kit that is described as a significant improvement over its prior kit. The company reports that this kit requires lower total protein input and, based on internal validation studies, can detect proteins in mixtures with very small amounts of input protein. Quantum-Si highlights that these capabilities are intended to help users process scarce biological samples and detect low-abundance proteins, including in applications related to signaling pathways.

Alongside these consumable kits, Quantum-Si has released a suite of data analysis tool enhancements. According to the company, these tools unlock detection of an additional amino acid (methionine), increase peptide alignment accuracy, and improve overall protein inference performance and interpretability. The company also notes that its analysis tools expand amino acid coverage toward a broader set of amino acids on its platform.

Proteus platform and technology roadmap

Quantum-Si has publicly discussed an upcoming platform called Proteus. In its communications, the company describes Proteus as a development-stage platform intended to deliver higher sequencing performance compared to its existing Platinum Pro system. Quantum-Si has reported successful sequencing runs on a prototype Proteus unit and indicates that prototype runs have met or exceeded the performance of the current platform in internal evaluations.

The company has outlined a technology roadmap that includes:

• Progress toward coverage of all 20 amino acids using its amino acid recognizer program.
• Development of a controlled cleavage sequencing chemistry that, when combined with the Proteus architecture, is expected by the company to enable very high numbers of sequencing reads.
• A suite of post-translational modification (PTM) methods that Quantum-Si plans to utilize to support broad PTM analysis capabilities on the Proteus platform.

Quantum-Si presents this roadmap as part of its long-term plan to expand sequencing performance, output, and cost characteristics of its proteomics platforms. The company describes its pipeline as focused on scaling sequencing capabilities and enhancing the range of protein features that can be analyzed, including PTMs.

Commercialization and customer access

From its public statements, Quantum-Si is in the early stages of commercialization of its proteomics technology. The company reports revenue from product and service sales and notes that it is working through the initial stages of commercialization, including managing variability in gross margin related to the timing and mix of instrument and consumable sales.

Quantum-Si has described a range of instrument acquisition options, including an instrument placement program. The company indicates that this program has been used to deploy its sequencing technology to new academic customers who may not have been able to acquire the platform through traditional capital purchases. Quantum-Si has stated that increasing the number of customers using its technology is intended to drive awareness, enable studies that can lead to publications, and support consumable volume and revenue.

Capital markets activity and corporate agreements

Quantum-Si is a U.S. public company incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission. Its Class A common stock trades on Nasdaq under the symbol QSI, and its redeemable warrants trade under the symbol QSIAW. The company has entered into various capital markets and financing arrangements, as reflected in its Form 8-K filings.

In one such filing, Quantum-Si disclosed a registered direct offering in which it agreed to issue and sell shares of Class A common stock and pre-funded warrants to an institutional investor, with gross proceeds described in the filing. The company indicated that it intends to use the net proceeds for product development objectives, including its Proteus platform, general commercialization, manufacturing development of its products, research and development, and other general corporate purposes.

Quantum-Si has also entered into a Sales Agreement with a sales agent that allows it to offer and sell shares of Class A common stock from time to time in an at-the-market offering, subject to an effective shelf registration statement. The company notes that it may choose not to sell any shares under this agreement and that it can suspend or terminate the arrangement according to its terms.

Additionally, Quantum-Si has reported the termination of a material lease agreement for premises in New Haven, Connecticut, through a Settlement and Mutual Release Agreement with its landlord. Under that agreement, the lease was terminated early, and the company agreed to pay a termination fee and surrender its security deposit, with no further rent obligations after the early termination date.

Equity compensation and employee inducement plans

Quantum-Si uses equity-based compensation as part of its hiring and retention strategy. The company has a 2023 Inducement Equity Incentive Plan, which it states is used exclusively for grants of equity awards to individuals who were not previously employees (or who are rehired after a bona fide period of non-employment). Under this plan, the company has disclosed multiple grants of restricted stock units (RSUs) to new employees as an inducement to join Quantum-Si, in accordance with Nasdaq Listing Rule 5635(c)(4). These RSUs vest over time, subject to continued employment and the terms of the plan and award agreements.

Financial reporting and operating profile

Quantum-Si provides quarterly and annual financial statements, including condensed consolidated balance sheets and statements of operations and comprehensive loss. The company reports revenue from product and service sales, cost of revenue, research and development expenses, selling, general and administrative expenses, and other items such as lease termination expense and legal settlement expense. It also discloses non-GAAP measures such as adjusted total operating expenses and adjusted EBITDA, with reconciliations to the most directly comparable GAAP measures.

In its financial commentary, Quantum-Si notes that it continues to manage operating expenses while funding its Proteus development program. The company has also discussed its cash, cash equivalents, and marketable securities balance and has indicated the period over which it anticipates this capital can support operations, based on its internal expectations.

Location and regulatory status

According to its SEC filings, Quantum-Si’s principal executive offices are located in Branford, Connecticut. The company is incorporated in Delaware and is subject to the reporting requirements of the Securities Exchange Act of 1934. Its Class A common stock and redeemable warrants are listed on The Nasdaq Stock Market LLC.

FAQs about Quantum-Si (QSI)

• What does Quantum-Si Incorporated do?
  Quantum-Si is a proteomics technology and life sciences company that develops and commercializes research tools for protein detection and analysis. It has designed a hardware, consumable, and software solution built on a proprietary single-molecule detection platform that enables Next-Generation Protein Sequencing.
• How does Quantum-Si describe its proteomics platform?
  The company describes its platform as a benchtop system that brings single-molecule protein analysis to laboratories, enabling real-time kinetic-based detection and allowing researchers to move beyond traditional, multistep workflows to access dynamic, functional protein insights.
• What industry is Quantum-Si part of?
  Quantum-Si is classified in the Other Measuring and Controlling Device Manufacturing industry within the manufacturing sector, with a specific focus on proteomics research tools and single-molecule protein analysis technology.
• What is the significance of Quantum-Si’s NGPS platform?
  Quantum-Si reports that its proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing, which it describes as the ability to sequence proteins. This capability underlies its benchtop instruments, consumable kits, and software tools for protein analysis.
• What are the V4 Sequencing Kit and Version 3 Library Preparation Kit?
  The V4 Sequencing Kit is a chemistry kit compatible with Quantum-Si’s Platinum and Platinum Pro instruments that, according to the company, improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The Version 3 Library Preparation Kit is described as a more sensitive library prep kit that supports lower protein input and detection of low-abundance proteins in mixtures.
• What is the Proteus platform?
  Proteus is a development-stage platform that Quantum-Si has highlighted in its investor communications. The company reports successful sequencing on prototype Proteus units and describes a roadmap that includes expanded amino acid coverage, controlled cleavage sequencing chemistry, and PTM analysis capabilities, with the goal of achieving higher sequencing performance than its current system.
• How does Quantum-Si approach commercialization of its technology?
  Quantum-Si reports revenue from product and service sales and notes that it is in the initial stages of commercialization. It has implemented an instrument placement program and other acquisition options to deploy its sequencing technology to customers, including academic users, with the aim of driving awareness, supporting studies and publications, and generating consumable usage.
• Where is Quantum-Si headquartered?
  According to its SEC filings, Quantum-Si’s principal executive offices are in Branford, Connecticut. The company is incorporated in Delaware and its securities are listed on The Nasdaq Stock Market LLC.
• What stock symbols are associated with Quantum-Si?
  Quantum-Si’s Class A common stock trades on Nasdaq under the symbol QSI. Its redeemable warrants, each exercisable for one share of Class A common stock at a specified exercise price, trade under the symbol QSIAW.
• How does Quantum-Si use equity compensation?
  The company has a 2023 Inducement Equity Incentive Plan used exclusively for equity awards to new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Under this plan, Quantum-Si has granted restricted stock units that vest over time, subject to continued employment and plan terms.